Author

NATALIE SRODA

Observed name: Natalie Sroda

Observed institutions: Gilead Sciences (United States), VMware (United States)

ORCID: 0000-0003-0251-7196

Observed ORCID: 0000-0003-0251-7196

OpenAlex ID: A5039660738

Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis

2023 · Claudia D. Fuchs, Natalie Sroda, et al. · JHEP Reports · 21

An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial

2026 · Xiaoxu Li, Giorgia Benegiamo, et al. · Nature Medicine · 8

The Discovery of GS-1291269: A Neutral Ketohexokinase (KHK) Inhibitor with an Unusual Thietane Amine Functional Group

2025 · Zachary A. Kasun, Xiaomin Liang, et al. · Journal of Medicinal Chemistry · 2

899-P: Combinations of the Mitochondrial Protonophore TLC-6740 and/or the ACC2 Inhibitor TLC-3595 Provide Additive Glycemic Benefits to Semaglutide (SEMA) in db/db Mice

2024 · ARCHANA VIJAYAKUMAR, NATALIE SRODA, et al. · Diabetes · 2

849-P: Antidiabetic Effects of TLC-3595, a Selective ACC2 Inhibitor, in ZDF Rats

2023 · ARCHANA VIJAYAKUMAR, EISUKE MURAKAMI, et al. · Diabetes · 2

1694-P: De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 with Semaglutide Improves Weight Loss and Preserves Lean Mass in Dio Mice

2025 · MONIKA SHARMA, NATALIE SRODA, et al. · Diabetes · 1

1637-P: TLC-6740, a Liver-Targeted Mitochondrial Protonophore, Increases Energy Expenditure and Lipid Utilization in Obese Mice

2024 · NATALIE SRODA, ARCHANA VIJAYAKUMAR, et al. · Diabetes · 1

1686-P: Novel Combination of a Mitochondrial Protonophore (MP) and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice

2025 · NATALIE SRODA, MONIKA SHARMA, et al. · Diabetes

1687-P: Sequential Combination of the Mitochondrial Protonophore (MP) TLC-6740 with Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice

2025 · NATALIE SRODA, MONIKA SHARMA, et al. · Diabetes

TLC-2716, a novel Liver X Receptor (LXR) inverse agonist with high enterohepatic but low systemic exposure

2025 · Eisuke Murakami, Archana Vijayakumar, et al. · Drug Metabolism and Pharmacokinetics

TLC-3595, a selective acetyl-CoA carboxylase 2 (ACC2) inhibitor, improves steatosis and fibrosis in murine models of NASH via pleiotropic mechanisms

2023 · Archana Vijayakumar, Eisuke Murakami, et al. · Journal of Hepatology

A Novel, Small-Molecule Inhibitor of Ketohexokinase Attenuates Tubular Injury, Immune Cell Infiltration, and Renal Failure in Models of Acute and Chronic Kidney Injury

2022 · Natalie Sroda, Shawn S. Badal, et al. · Journal of the American Society of Nephrology

Inhibition of tumour progression locus 2 (TPL2) halts the progression of liver fibrosis in a stringent long term choline deficient high-fat diet (CdHFD) rat model

2022 · Milessa Silva Afonso, Rowena Suriben, et al. · Journal of Hepatology

Works count: 13

Citation count: 37

H-index: 2

I10-index: 1